Summary
Cencora, Inc. (formerly AmerisourceBergen Corporation) has announced a significant change in its reporting structure, effective from the first quarter of fiscal year 2022. This re-alignment is a direct result of the company's expanded international presence, particularly following the June 2021 acquisition of Alliance Healthcare. The new structure will consolidate operations into two distinct reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions. This strategic move aims to provide a clearer and more accurate reflection of the company's global business operations for investors. The company is furnishing supplemental, unaudited revised segment information for fiscal 2021 to allow for easier analysis of these structural changes. Investors should pay close attention to how these new segmentations impact future financial reporting and performance analysis.
Key Highlights
- 1Cencora is re-aligning its reporting structure into two segments: U.S. Healthcare Solutions and International Healthcare Solutions, effective Q1 fiscal 2022.
- 2This change is driven by the expanded international presence, especially after the Alliance Healthcare acquisition.
- 3The U.S. Healthcare Solutions segment will include legacy Pharmaceutical Distribution Services (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.
- 4The International Healthcare Solutions segment will encompass Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.
- 5Profarma and Profarma Specialty are being reclassified into the new international segment.
- 6The company is providing unaudited revised segment information for fiscal 2021 to aid investor analysis of the new structure.
- 7This disclosure is furnished under Regulation FD and is not considered 'filed' under Section 18 of the Exchange Act unless expressly stated otherwise.